Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of the Skin, Subcutaneous Tissue and BreastDRG 583-mastectomy-for-malignancy-without-cc-mcc
    Ask Trek AI about this page

    Mastectomy for Malignancy without CC/MCC: Inpatient Reimbursement Overview

    DRG 583 applies to inpatient mastectomy for malignancy without Complication or Comorbidity or Major Complication or Comorbidity; it defines the clinical scope as surgical treatment of breast cancer without additional complicating conditions. Assignment to this Diagnosis-Related Group matters for inpatient reimbursement because it determines the prospective payment amount that Medicare provides for routine mastectomy hospitalizations.

    Customize your policy alerts

    Sign up for drg 583 policy alerts

    Get alerted when payer policies referencing 583 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 583 Overview

    DRG 583 covers inpatient admissions for mastectomy performed to treat breast malignancy when no Complication or Comorbidity and no Major Complication or Comorbidity are present. This Diagnosis-Related Group applies to surgical management of primary breast cancer and related perioperative care during a single inpatient stay. It matters for Medicare payment because cases assigned to this Diagnosis-Related Group receive a specific prospective payment that reflects expected resource use for straightforward mastectomy encounters. Accurate coding of diagnoses and procedures determines assignment to this Diagnosis-Related Group and the associated reimbursement.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Perioperative surgical technique and reconstruction outcomes: randomized or observational studies comparing different mastectomy approaches (skin-sparing, nipple-sparing, total mastectomy) and immediate breast reconstruction strategies (implant-based vs autologous tissue) in patients undergoing mastectomy for early-stage breast cancer without major comorbidities. These studies focus on short-term surgical metrics (operative time, blood loss, wound complications, reoperation), oncologic safety (margin status, local recurrence within early follow-up), and patient-reported cosmetic and quality-of-life outcomes. This research is relevant to surgeons, hospital administrators, and payers because surgical approach and reconstruction choices directly affect resource utilization, length of stay, complication rates, readmissions, and downstream costs for this DRG population.
    • Comparative effectiveness of perioperative care bundles and enhanced recovery protocols: trials and cohort studies testing ERAS pathways, antibiotic prophylaxis timing/duration, thromboembolism prevention regimens, and pain-management strategies (opioid-sparing multimodal analgesia) in otherwise healthy mastectomy patients without CC/MCC. These studies evaluate impacts on immediate postoperative recovery metrics — pain control, opioid consumption, time to ambulation, length of stay, and incidence of surgical site infection — and may stratify by age, BMI, or smoking status. Findings inform clinical pathways that can reduce complications and resource use, making them highly pertinent for clinicians optimizing care and for payers seeking to control costs and improve quality metrics for DRG 583 cases.
    • Post-discharge outcomes, surveillance, and rehabilitation studies: prospective registries and longitudinal cohort studies following patients after discharge to assess wound healing, lymphedema incidence, psychosocial outcomes, and adherence to adjuvant oncologic treatments in patients who had mastectomy for malignancy without significant comorbidity. Research in this area examines predictors of readmission, outpatient service utilization (wound care, physical therapy), and long-term functional and quality-of-life trajectories, often including interventions such as early physiotherapy or patient education to prevent lymphedema and improve recovery. This evidence is critical for care managers and payers because it identifies high-risk subgroups that may need targeted outpatient resources to prevent costly readmissions and to optimize longitudinal outcomes for patients classified under this DRG.

    Related Codes

    570-SKIN-DEBRIDEMENT-WITH-MCC

    Skin Debridement with Major Complication or Comorbidity: Inpatient Reimbursement Overview

    571-SKIN-DEBRIDEMENT-WITH-CC

    Skin Debridement with CC: Inpatient Reimbursement Overview

    572-SKIN-DEBRIDEMENT-WITHOUT-CC-MCC

    Skin Debridement without CC/MCC: Inpatient Reimbursement Overview

    573-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

    Skin Graft for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

    574-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-CC

    Skin Graft for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

    575-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITHOUT-CC-MCC

    Skin Graft for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

    576-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

    Skin Graft Except for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

    577-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-CC

    Skin Graft Except for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

    578-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITHOUT-CC-MCC

    Skin Graft Except for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

    579-OTHER-SKIN-SUBCUTANEOUS-TISSUE-AND-BREAST-PROCEDURES-WITH-MCC

    Other Skin, Subcutaneous Tissue and Breast Procedures with MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 31

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.